Table 2. Summary estimates of diagnostic criteria and their 95% confidence intervals (95% CI).

Analysis	No. of studies	SEN (95%CI)	SPE (95%CI)	PLR (95%CI)	NLR (95%CI)	DOR (95%CI)	AUC (95%CI)
Gastric cancer	47	0.77 (0.72–0.80)	0.81 (0.77–0.84)	4.0 (3.2–4.9)	0.29 (0.24–0.36)	14 (9–20)	0.86 (0.82–0.88)
MiRNA profiling
Single-miRNA	39	0.75 (0.70–0.79)	0.80 (0.75–0.84)	3.7 (2.9–4.6)	0.32 (0.26–0.39)	11 (8–17)	0.84 (0.80–0.87)
Multiple-miRNAs	8	0.87 (0.75–0.94)	0.84 (0.75–0.91)	5.6 (3.1–10)	0.15 (0.07–0.33)	37 (10–134)	0.92 (0.89–0.94)
Source material
Plasma-based	26	0.82 (0.78–0.86)	0.85 (0.80–0.89)	5.6 (4.0–7.8)	0.21 (0.16–0.27)	27 (16–47)	0.90 (0.88–0.93)
Serum-based	21	0.67 (0.61–0.73)	0.74 (0.69–0.78)	2.5 (2.1–3.1)	0.44 (0.37–0.53)	6 (4–8)	0.77 (0.73–0.80)
Colorectal cancer	47	0.73 (0.69–0.77)	0.80 (0.76–0.83)	3.6 (3.0–4.2)	0.34 (0.29–0.39)	11 (8–14)	0.83 (0.80–0.86)
MiRNA profiling
Single-miRNA	29	0.68 (0.62–0.73)	0.77 (0.72–0.81)	2.9 (2.4–3.5)	0.42 (0.36–0.50)	7 (5–10)	0.79 (0.75–0.82)
Multiple-miRNAs	18	0.81 (0.77–0.84)	0.83 (0.79–0.87)	4.9 (3.8–6.2)	0.23 (0.19–0.27)	22 (15–30)	0.89 (0.86–0.91)
Source material
Plasma-based	33	0.72 (0.65–0.77)	0.77 (0.73–0.80)	3.1 (2.5–3.7)	0.37 (0.30–0.46)	8 (6–12)	0.81 (0.77–0.84)
Serum-based	14	0.77 (0.72–0.81)	0.85 (0.80–0.89)	5.1 (3.9–6.7)	0.28 (0.23–0.33)	18 (13–26)	0.88 (0.85–0.90)
Esophageal cancer	13	0.79 (0.74–0.84)	0.85 (0.81–0.89)	5.4 (4.1–7.1)	0.24 (0.19–0.31)	22 (14–35)	0.89 (0.86–0.92)
All studies	107	0.75 (0.73–0.78)	0.81 (0.79–0.83)	4.0 (3.5–4.5)	0.30 (0.27–0.34)	13 (10–16)	0.85 (0.82–0.88)

CI, confidence interval; SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve.